This webinar will provide information about recurrent or metastatic cervical cancer, followed by an introduction to the clinical data for tisotumab vedotin, an investigational agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.


  • Deepak Singh, PharmD

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a payer with FormularyDecisions.

Click here for additional information and registration details.


Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.